186 related articles for article (PubMed ID: 30788859)
21. Resolution of CMV Infection in the Bowel on Vedolizumab Therapy.
Rawa-Gołębiewska A; Lenarcik M; Zagórowicz E
J Crohns Colitis; 2019 Sep; 13(9):1234-1235. PubMed ID: 30860256
[No Abstract] [Full Text] [Related]
22. Vedolizumab for the treatment of ulcerative colitis.
Stallmach A; Schmidt C; Teich N
Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
de Freitas LF; Feitosa MR; Féres O; Parra RS
Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
[No Abstract] [Full Text] [Related]
24. Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-α drug failure.
Sáez-González E; Aguas M; Huguet JM; Nos P; Beltrán B
Dig Liver Dis; 2018 Apr; 50(4):415-417. PubMed ID: 29397323
[No Abstract] [Full Text] [Related]
25. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.
Verstockt B; Claeys C; De Hertogh G; Van Assche G; Wolthuis A; D'Hoore A; Vermeire S; Ferrante M
United European Gastroenterol J; 2019 Nov; 7(9):1215-1225. PubMed ID: 31700634
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.
Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M
Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302
[TBL] [Abstract][Full Text] [Related]
27. Letter: Vedolizumab in Pregnancy.
Sheridan J; Cullen G; Doherty G
J Crohns Colitis; 2017 Aug; 11(8):1025-1026. PubMed ID: 27993997
[No Abstract] [Full Text] [Related]
28. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab.
Dalal RS; Ananthakrishnan AN; Hamilton MJ; Winter RW
Dig Dis Sci; 2021 Mar; 66(3):733-737. PubMed ID: 33569666
[No Abstract] [Full Text] [Related]
29. A Case of Vedolizumab-induced Acute Allergic Reaction in a Patient With Refractory Ulcerative Colitis.
Xie Y; Li H; Zhou L; Tian F
Inflamm Bowel Dis; 2022 Jul; 28(7):e103. PubMed ID: 35134937
[No Abstract] [Full Text] [Related]
30. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
31. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
32. Positioning Therapy for Ulcerative Colitis.
Grinspan A; Kornbluth A
Curr Gastroenterol Rep; 2015 Aug; 17(8):29. PubMed ID: 26143627
[TBL] [Abstract][Full Text] [Related]
33. Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy.
Roblin X; Paul S; Ben-Horin S
J Crohns Colitis; 2018 Feb; 12(3):379-380. PubMed ID: 29088342
[No Abstract] [Full Text] [Related]
34. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.
Pellet G; Stefanescu C; Carbonnel F; Peyrin-Biroulet L; Roblin X; Allimant C; Nachury M; Nancey S; Filippi J; Altwegg R; Brixi H; Fotsing G; de Rosamel L; Shili S; Laharie D;
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):494-501. PubMed ID: 30213584
[TBL] [Abstract][Full Text] [Related]
35. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
[TBL] [Abstract][Full Text] [Related]
36. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
Yamamoto-Furusho JK; Uzcanga LF
Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
[TBL] [Abstract][Full Text] [Related]
37. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
38. Predictors of response to steroid therapy in patients with acute, severe ulcerative colitis.
Farkas K; Bálint A; Bor R; Nagy F; Szepes Z; Molnár T
Scand J Gastroenterol; 2014 Jul; 49(7):899-900. PubMed ID: 24742153
[No Abstract] [Full Text] [Related]
39. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
Mocciaro F; Orlando A; Scimeca D; Cottone M
Recenti Prog Med; 2007 Nov; 98(11):560-4. PubMed ID: 18044405
[TBL] [Abstract][Full Text] [Related]
40. Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease.
Conrad MA; Stein RE; Maxwell EC; Albenberg L; Baldassano RN; Dawany N; Grossman AB; Mamula P; Piccoli DA; Kelsen JR
Inflamm Bowel Dis; 2016 Oct; 22(10):2425-31. PubMed ID: 27598742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
